CN Bio logoCN Bio logoCN Bio logoCN Bio logo
  • Products
    • Explore our solutions


      PhysioMimix™ products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Multi-organ models

      Support packages

      • PhysioMimix™ support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix™ products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • Oncology
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

      Oncology icon

      Oncology

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

      • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place.

      • CN Bio appoints Dr Paul Brooks as Chief Executive Officer

      View all news

      Upcoming Events

      • SLAS2023

      • SOT 2023

      • WORD 2023

      • SLAS Europe 2023

      • MPS World Summit 2023

      View all events

      Join the team!

      View all jobs
  • Contact
  • Products
    • PhysioMimix™ OOC Microphysiological Systems
    • Consumables
      • PhysioMimix™ multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to footer
Chat live with an expert

Fully human in vitro gut-liver model of non-alcoholic steatohepatitis

June 11, 2017 by

Resource > Posters >

Fully human in vitro gut-liver model of non-alcoholic steatohepatitis


American Association for the Study of Liver Diseases (AASLD)

Filed under: Disease modeling and NAFLD/NASH

Fully human in vitro gut liver model of NASH EDIT |

Kostrzewski et al 

Non-Alcoholic Fatty Liver Disease(NAFLD) represents a wide spectrum of liver abnormalities with the most severe cases involving progressive liver injury in the form Non-Alcoholic Steatohepatitis (NASH). Key characteristics of NASH include lipid accumulation in hepatocytes, chronic inflammation and extracellular matrix deposition, leading to fibrosis. NASH is the liver manifestation of the metabolic syndrome, with close association with insulin resistance, obesity and Type 2 diabetes. The interaction between the liver and the gut (the “gut-liver axis”), is now known to play a critical role in NAFLD onset and progression. Dietary factors and gut microbiota can both alter intestinal barrier function, leading to metabolic endotoxemia and low-grade inflammation which will contribute to the development of NAFLD.​

There is a requirement for better preclinical models to understand the molecular mechanisms underlying NAFLD/NASH. Particularly models that mimic disease progression in the liver with linked interactions to the gut, adipose tissue and immune system will have the highest translational relevance. This is particularly prevalent as there remains no FDA approved drugs for the treatment of NAFLD/NASH.​

Using perfused microphysiological cell culture systems, we aimed to develop a fully human in vitro NAFLD/NASH model, utilizing primary human hepatocytes (PHH), Kupffer (HK) and hepatic stellate cells (HSC). The complexity of this model was further enhanced by combining the NASH liver model with an in vitro gut model to allow the interactions of the two organs to be studied.​

Utilizing perfused MPS culture platforms, we have generated fully human models of NASH liver and NASH gut/liver. Combining the gut and NASH liver models, we demonstrate gut-liver crosstalk where by inflammation from the NASH liver was increased when LPS leaked from gut epithelium. These in vitro NASH models are ideally suited to exploring the molecular mechanisms that underlie the development of human NASH and will be a useful tool for analyzing the efficacy of novel anti-NASH therapeutics against a range of different target pathways.

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

+44 (0) 1223 737941

Privacy | Cookies | Terms | Regulatory | Accessibility

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. 978184563

Latest news

  • The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system January 17, 2023
  • The U.S. FDA Modernization Act 2.0. Now the animal testing mandate is removed, learn what can be embraced in its place. January 9, 2023
  • CN Bio appoints Dr Paul Brooks as Chief Executive Officer December 19, 2022

Upcoming events

MPS World Summit 2023 June 26-30, 2023

SLAS Europe 2023 May 22-26, 2023

SLAS2023 February 25 - March 1, 2023